Pharming Group (NASDAQ:PHAR – Get Rating) – Oppenheimer issued their FY2022 earnings estimates for shares of Pharming Group in a note issued to investors on Sunday, October 30th. Oppenheimer analyst H. Singh anticipates that the company will post earnings per share of $0.04 for the year. The consensus estimate for Pharming Group's current full-year earnings is $0.03 per share. Oppenheimer also issued estimates for Pharming Group's Q4 2022 earnings at $0.00 EPS and FY2024 earnings at $0.03 EPS.
Get Pharming Group alerts:Separately, TheStreet upgraded shares of Pharming Group from a "d+" rating to a "c" rating in a report on Monday, August 15th.
Pharming Group Stock Performance
Shares of PHAR stock opened at $11.40 on Wednesday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 4.68 and a current ratio of 5.40. The company has a market capitalization of $744.19 million, a P/E ratio of 27.81 and a beta of -0.32. The company's 50 day moving average price is $10.84 and its two-hundred day moving average price is $9.20. Pharming Group has a 52 week low of $6.10 and a 52 week high of $12.98.Pharming Group (NASDAQ:PHAR – Get Rating) last announced its earnings results on Thursday, August 4th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.01 by $0.03. The firm had revenue of $50.15 million for the quarter, compared to the consensus estimate of $51.99 million. Pharming Group had a net margin of 14.90% and a return on equity of 8.98%.
About Pharming Group
(Get Rating)
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema.
Featured Articles
- Get a free copy of the StockNews.com research report on Pharming Group (PHAR)
- New Revenue Strategy, Strong Earnings, Apple Remains a Buy
- Chesapeake Energy Focus on Natural Gas Leads to Strong Results
- Devon Energy Lower After Beating Q3 Views But Slashing Dividend
- Are Investors Bailing on Travel America as Diesel Shortages Loom?
- Sell-Side Interest Drives Mondelez Higher
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.